CLOs on the Move

RetireeFirst

www.retireefirst.com

 
Established in 2005 and currently servicing over 250 clients, RetireeFirst (formerly LaborFirst) is the premier retiree benefit management solutions and advocacy service provider, proven to enhance the experience and outcomes for group plan sponsors, employers, and their retirees. Our sole focus on retiree benefits means our solutions and services, combined with our people-centric approach, deliver immediate savings, significantly reduce administrative burden, and help preserve the benefits retirees deserve. Our unparalleled retiree advocacy service connects members to programs that help improve their health and wellness, resulting in happier and more engaged members. We go above and beyond for our clients, and ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.retireefirst.com
  • 1000 Midlantic Drive Suite 100
    Mount Laurel, NJ USA 08054
  • Phone: 800.716.0774

Executives

Name Title Contact Details

Similar Companies

Most Products Inc

Most Products Inc is a Plainwell, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Marshalltown Medical Sergical Center

Marshalltown Medical & Surgical Center (MMSC) is the only full service medical center in the area. The 125-bed, not-for-profit facility serves more than 60,000 residents with a wide variety of healthcare services and around-the-clock emergency care. MMSC includes a state-of-the-art Diagnostic Imaging Department, Cardiac Catheterization Lab and Rehabilitation Center, as well as four primary care clinics. The hospital is accredited by the Center for Medicare and Medicaid Services (CMS).

Lyons Lavey Nickel Swift

Lyons Lavey Nickel Swift is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Apara Autism Center

Apara Autism Centers provides ABA therapy services in Texas to empower autistic individuals with customized support and resources for better life quality.

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.